A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

NCT02645253 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma
Chronic Obstructive Pulmonary Disease COPD

Interventions

DRUG: AZD7594 inhalation powder (200 μg)
DRUG: AZD7594 inhalation powder (400 μg)
DRUG: AZD7594 pressurized inhalation suspension (200 μg)
DRUG: AZD7594 placebo inhalation powder
DRUG: AZD7594 placebo pressurized inhalation suspension

Sponsor

AstraZeneca